STRM.BIO raised $8 million in a Series Seed 2 financing to advance its non-viral gene delivery platform for in vivo cell engineering and gene therapy. The round included funding from Recordati, with continued participation from Boehringer Ingelheim Venture Fund and Delos Capital, plus new backing from Blue Bay Capital Fund; the Seed 2 round remains open with plans to close by Q1 2026.
Including a recent $8.4 million ARPA-H contract, the company said it has secured $16.4 million in recent funding as of Q4 2025. STRM.BIO’s megakaryocyte-derived vesicle (MV) platform is designed to deliver complex genetic cargo directly to bone marrow, enabling potential repeat dosing and aiming to address limitations of viral and synthetic delivery systems. The company plans to use proceeds to validate the platform, advance programs toward clinical trials—starting with Fanconi anemia—and support fundraising for a Series A.
KEY QUOTE:
“We are excited to welcome Recordati as one of our lead investors and to have the continued support from Boehringer Ingelheim Ventures, Delos, and Blue Bay. We believe our platform is transformative for hematological diseases and the field of non-viral gene delivery. Now, with the backing that includes two leading pharma investors, we are well-positioned to validate our platform and pipeline focus for in vivo modification of bone marrow cells with an initial focus on Fanconi anemia, a rare hematological disease, with the potential to expand into other rare diseases.”
Michael Luther, Ph.D., MBA, CEO, STRM.BIO
